Valeant sees Merz's $22 bet, raises Obagi bid to $24
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals raised its acquisition price for dermatology specialist Obagi Medical Products to $24 per share - 22% higher than the buyout the companies announced in March - in response to Merz Pharma Group's $22 per share bid for Obagi.